NO⢠/RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.
Int J Cancer
; 146(11): 3160-3169, 2020 06 01.
Article
em En
| MEDLINE
| ID: mdl-31609478
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is refractory to available treatments. Delineating the regulatory mechanisms of metabolic reprogramming, a key event in pancreatic cancer progression, may identify candidate targets with potential therapeutic significance. We hypothesized that inflammatory signaling pathways regulate metabolic adaptations in pancreatic cancer. Metabolic profiling of tumors from PDAC patients with a high- (>median, n = 31) and low-NOS2 (inducible nitric oxide synthase; Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Carcinoma Ductal Pancreático
/
Óxido Nítrico Sintase Tipo II
/
Subunidade alfa 3 de Fator de Ligação ao Core
/
Cinurenina
/
Óxido Nítrico
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Moldávia